石药集团新诺威制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》和石药集团新诺威制药股份有限公司（以下简称"新诺威"或"公司"） 《募集资金管理办法》的有关规定，现将公司 2023 年半年度募集资金存放与使 用情况专项说明如下： 上述募集资金到位情况已由信永中和会计师事务所（特殊普通合伙）审验， 并于 2023 年 2 月 22 日出具《验资报告》（报告号：XYZH/2023HZAA1B0061）。 公司已对募集资金采取了专户存储，并且公司与开户银行、独立财务顾问签订了 《募集资金三方监管协议》。 2、截至 2023 年 6 月 30 日募集资金净额使用情况及结余情况 一、募集资金基本情况 1、募集资金金额、资金到账时间 （1）首次公开发行募集资金情况 石药集团新诺威制药股份有限公司经中国证券监督管理委员会《关于核准石 药集团新诺威制药股份有限公司首次公开发行股票的批复》（证监许可[2019]288 号）核准，并经深圳证券交易所《关于石药集团新诺威制药股份有限公司人民币 普通股股票在创业板上市的通知》（深证上[ ...

证券代码： 300765 证券简称： 新诺威 石药集团新诺威制药股份有限公司投资者关系活动记录表 编号：2023-03 √特定对象调研 □分析师会议 投资者关系活 □媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □现场参观 □其他 | --- | --- | |--------------|------------------------------------------------------| | | 国信证券彭思语、国寿安保基金王雪莹、招银理财吴昆伦、 | | 参与单位名称 | 中信建投资管王晨宇、安信基金陈少波、华夏东方养老资产 | | | 管理有限公司蔡颖 | 时间 2023 年 6 月 7 日 (周三) 上午 9:30~10:30 地点 公司会议室 上市公司接待 人员姓名 董事会秘书兼财务总监：戴龙 一、对公司基本情况进行介绍。 二、互动问答。 问题 1、咖啡因业务的政策法规。 答复：咖啡因产品属于国家第二类精神药品，国家药品 监督管理部门对精神药品实行定点生产制度。需严格按照 投资者关系活 《麻醉药品和精神药品管理条例》进行生产和销售。根据河 动主要内容介 北省药品监督管理局每年出 ...

Group 1: Market Trends and Business Strategy - The demand for health supplements is continuously increasing due to the growing awareness of self-care among residents [2] - The company plans to launch new products in the health supplement sector to expand its product line and brand matrix [2] - The company aims to enhance its marketing network and market expansion efforts for health supplement products [2] Group 2: Financial Performance and Investments - The company reported an investment income of approximately 10 million RMB from Guoxin Huijin in 2022 [3] - The company is expected to benefit from exchange gains if the RMB depreciates against the USD [3] Group 3: Product Development and Sales Channels - The company is currently focusing on the construction of health supplement and caffeine product projects, which are progressing as planned [3] - The sales of health food products are primarily through offline pharmacies, with plans to increase online channel development in 2023 [3] - The company has obtained approvals for two non-fully nutritional special medical purpose foods and is accelerating the development of fully nutritional products [4] Group 4: Operational Insights - The production and sales of caffeine and acarbose products are operating normally, with all business activities proceeding in an orderly manner [3] - The company maintains a commitment to continuous product innovation to become an industry leader [4]

证券代码：300765 证券简称：新诺威 公告编号：2023-047 石药集团新诺威制药股份有限公司 关于参加河北辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，石药集团新诺威制药股份有限公司（以 下简称"公司"）将参加由河北证监局、河北省上市公司协会与深圳市全景网络 有限公司联合举办的"2023 年河北辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与 本次互动交流，活动时间为 2023 年 5 月 30 日（周二） 15:40-17:00。届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况等投资者关 心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 石药集团新诺威制药股份有限公司 董事会 2023 年 5 月 26 日 1 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥684,020,305, representing a 26.43% increase compared to ¥541,028,381 in the same period last year[5] - Net profit attributable to shareholders was ¥181,976,426, a 47.33% increase from ¥123,520,129 in Q1 2022[5] - Basic and diluted earnings per share increased to ¥0.2939, reflecting a 47.32% rise from ¥0.1995 in Q1 2022[5] - Total operating revenue for the current period reached ¥684,020,305, an increase of 26.4% compared to ¥541,028,381 in the previous period[26] - Net profit for the current period was ¥181,929,887, representing a 47.3% increase from ¥123,502,450 in the previous period[27] - The total profit for the current period was ¥215,261,824, an increase of 42.8% from ¥150,720,084 in the previous period[27] Cash Flow and Liquidity - The net cash flow from operating activities was ¥156,910,519, up 47.53% from ¥106,355,965 in the previous year[14] - Cash flow from operating activities generated a net amount of ¥156,910,520, compared to ¥106,355,966 in the previous period, marking a 47.5% increase[30] - The cash and cash equivalents balance at the end of the quarter was ¥2,799,277,798, a 63.81% increase from ¥1,708,827,432 at the end of the previous year[14] - Cash and cash equivalents at the end of the period totaled ¥2,799,277,798, up from ¥1,708,827,432, indicating a significant increase of 63.8%[31] - The company experienced a cash inflow from financing activities of ¥488,514,998, a significant turnaround from a cash outflow of -¥736,892 in the previous period[31] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥5,180,768,085, a 13.02% increase from ¥4,584,035,512 at the end of the previous year[5] - In Q1 2023, the total assets of the company reached CNY 5,180,768,084.66, an increase from CNY 4,584,035,512.38 at the beginning of the year, reflecting a growth of approximately 13.0%[22] - The total liabilities decreased to CNY 566,567,751.88 from CNY 639,841,376.25, indicating a reduction of approximately 11.4%[24] - The total current liabilities decreased to CNY 509,763,945.63 from CNY 582,768,085.61, a reduction of approximately 12.5%[24] Research and Development - The company reported a 79.97% increase in R&D expenses, totaling ¥13,545,879, compared to ¥7,526,576 in Q1 2022, indicating a focus on innovation[12] - Research and development expenses rose to ¥13,545,879, a substantial increase of 80.0% from ¥7,526,576 in the previous period[26] Shareholder Information - The company reported a total of 72,926,162 shares held by its largest shareholder, Shiyao Group Enbi Pharmaceutical Co., Ltd., which accounts for a significant portion of the total shares[18] - UBS AG acquired 3,211,586 shares during the non-public offering, with a lock-up period ending on September 9, 2023[18] - The company has not released any restricted shares during this quarter, maintaining a total of 72,926,162 restricted shares[18] - The company has committed to a 36-month lock-up period for shares issued in the recent transaction, ensuring stability in shareholder structure[18] - The top ten shareholders collectively hold a significant number of unrestricted shares, indicating strong institutional support[17] Strategic Initiatives - The company plans to expand its market presence and is focusing on new product development and technological advancements[17] - The first quarter performance indicates a strong upward trend in user data and market engagement, reflecting the effectiveness of recent strategies[17] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[17] - Future guidance suggests continued growth in revenue and user base, driven by strategic initiatives and market expansion efforts[17] Other Financial Metrics - Accounts receivable financing increased by 51.25% to ¥172,533,899 due to higher revenue and increased bank acceptance bills received[10] - The company experienced a 35.50% decrease in contract liabilities, down to ¥44,025,922, attributed to a reduction in advance payments received[10] - The company's accounts receivable decreased to CNY 439,056,492.37 from CNY 481,379,233.73, a decline of approximately 8.8%[23] - The inventory level decreased to CNY 229,119,007.12 from CNY 238,125,791.53, reflecting a decrease of about 3.8%[23] - The company's long-term investments slightly decreased to CNY 252,784,264.20 from CNY 253,488,895.12, a minor decline of about 0.3%[23]

Financial Performance - The company's revenue for Q1 2023 reached ¥684,020,305, representing a 26.43% increase compared to ¥541,028,381 in the same period last year[5] - Net profit attributable to shareholders was ¥181,976,426, a 47.33% increase from ¥123,520,129 in Q1 2022[5] - The net profit after deducting non-recurring gains and losses was ¥179,439,429, reflecting a 60.88% increase from ¥111,537,005 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 684,020,305, representing an increase of 26.4% compared to CNY 541,028,381.87 in the same period last year[23] - Net profit for Q1 2023 reached CNY 181,929,887.41, representing a 47.2% increase from CNY 123,502,450.15 in Q1 2022[24] - The company reported a total comprehensive income of CNY 181,810,781.12 for Q1 2023, up from CNY 123,843,650.92 in the same period last year[25] - Basic and diluted earnings per share for Q1 2023 were CNY 0.2939, compared to CNY 0.1995 in Q1 2022, marking a 47.3% increase[25] Cash Flow and Liquidity - Operating cash flow net amount was ¥156,910,520, up 47.53% from ¥106,355,966 in Q1 2022[12] - Cash and cash equivalents at the end of Q1 2023 were ¥2,799,277,798, a 63.81% increase from ¥1,708,827,432 at the end of the previous year[12] - The company's cash and cash equivalents at the end of Q1 2023 amounted to CNY 2,802,092,881.57, up from CNY 2,195,684,427.95 at the beginning of the year, reflecting a growth of 27.6%[20] - The company raised CNY 488,799,998.48 through financing activities in Q1 2023, compared to a cash outflow of CNY 736,892.33 in the same period last year[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥5,180,768,085, a 13.02% increase from ¥4,584,035,512 at the end of the previous year[5] - The total assets as of March 31, 2023, were CNY 5,180,768,084.66, compared to CNY 4,584,035,512.38 at the beginning of the year, indicating an increase of 13.0%[21] - The total liabilities decreased from CNY 639,841,376.25 at the beginning of the year to CNY 566,567,751.88, a reduction of 11.4%[21] - The equity attributable to shareholders of the parent company increased to CNY 4,605,653,369.51 from CNY 3,935,600,634.14, marking a growth of 17.0%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,983, with the top 10 shareholders holding 73.35% of the shares[13] - The total number of unrestricted shares held by the top 10 shareholders includes 404,135,550 shares held by Shiyao Group Enbipu Pharmaceutical Co., Ltd.[14] - UBS AG holds 3,211,586 shares, representing 0.51% of the total shares[14] - The total number of shares held by the top shareholder, Shiyao Group Enbipu Pharmaceutical Co., Ltd., is 404,135,550 shares, all of which are ordinary shares[14] - The total number of shares held by Hong Kong Central Clearing Limited is 6,052,856, representing 0.93% of the total shares[14] Research and Development - The company's R&D expenses increased by 79.97% to ¥13,545,879 from ¥7,526,576 in the same period last year, indicating a focus on innovation[11] - Research and development expenses increased to CNY 13,545,879.02, up 80.5% from CNY 7,526,575.82 in the previous year[24] Operational Highlights - The company completed the election of a new board of directors and supervisory board on April 7, 2023, along with the appointment of new senior management[18] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[18] - Total operating costs for Q1 2023 were CNY 472,576,687.19, an increase of 22.4% compared to CNY 386,256,108.97 in Q1 2022[24] - The company experienced a foreign exchange loss of CNY 4,787,109.33 during Q1 2023, compared to a gain of CNY 81,750.42 in Q1 2022[28]

石药集团新诺威制药股份有限公司（以下简称"公司"）已于 2023 年 3 月 17 日披露公司《2022 年年度报告》，为使投资者进一步了解公司的财务状况、经 营情况及公司发展规划，公司定于 2023 年 4 月 4 日（星期二）15:00-17:00 在全 景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举 行，投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次 年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长潘卫东先生、董事兼总经理 韩峰先生、独立董事徐一民先生、董事会秘书兼财务总监杜英女士、保荐代表人 张翊维先生。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 3 日 14:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。 公司将在 2022 年度网上业绩说明会上，对投资者普遍关注的问题进行回答。 证券代码：300765 证券简称：新诺威 公告编号：2023-031 石药集团新 ...

Financial Performance - The company reported a net profit that has been negative for the last three accounting years, indicating potential concerns regarding its ongoing viability [11]. - The company's operating revenue for 2022 was ¥2,626,488,832.63, representing a 42.00% increase compared to ¥1,849,677,007.18 in 2021 [13]. - The net profit attributable to shareholders for 2022 was ¥726,277,891.97, an increase of 84.70% from ¥393,228,489.93 in 2021 [13]. - The net profit after deducting non-recurring gains and losses reached ¥657,608,747.31, marking a 120.31% increase compared to ¥298,498,249.98 in 2021 [13]. - The net cash flow from operating activities was ¥640,717,518.79, up 119.36% from ¥292,085,994.15 in the previous year [13]. - The total assets at the end of 2022 amounted to ¥4,584,035,512.38, reflecting a 22.53% increase from ¥3,741,208,950.36 at the end of 2021 [13]. - The net assets attributable to shareholders increased by 19.65% to ¥3,935,600,634.14 from ¥3,289,370,322.06 in 2021 [13]. - The company reported a basic earnings per share of ¥1.1734 for 2022, an increase of 84.70% from ¥0.6353 in 2021 [13]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 15% compared to the previous year [32]. - The company reported a gross margin of 45%, maintaining a stable margin despite rising raw material costs [32]. - The company’s main business revenue for 2022 was approximately CNY 2.57 billion, with a gross profit margin of 43.58%, reflecting a year-on-year revenue increase of 43.43% [47]. Market Expansion and Product Development - The company is focused on expanding its market presence and enhancing its product offerings through new technology and product development initiatives [1]. - The company has established subsidiaries in the United States and Germany, indicating its international expansion strategy [5]. - The health food industry in China is experiencing rapid growth, with increasing consumer demand for functional foods and health management products [21]. - The company is the largest producer of synthetic caffeine globally, with a significant market share in the functional food and beverage sector [25]. - The company has an annual production capacity of approximately 280 tons for acarbose, making it the largest acarbose raw material producer in China [25]. - The company is actively pursuing market expansion through new product registrations and certifications, enhancing its competitive position in the pharmaceutical industry [28]. - The company aims to expand its market presence through the development of new health food products and technologies [31]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies with complementary health products [32]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years [109]. Research and Development - The company is focused on research and development to innovate and improve its product offerings, ensuring alignment with market demands and regulatory standards [28]. - The R&D team focuses on improving production processes for caffeine products and developing new resources and technologies in health food [58]. - The company is investing in R&D for new technologies, with a budget allocation of 200 million RMB aimed at enhancing product efficacy and safety [32]. - The company has reported a significant focus on research and development, particularly in new drug development and biopharmaceuticals, to enhance market competitiveness [131]. Compliance and Regulatory Matters - The company adheres to multiple regulatory frameworks, including the Food Safety Law and Drug Administration Law, ensuring compliance in its operations [23][24]. - The company’s financial reports are audited by Xinyong Zhonghe Accounting Firm, ensuring compliance and accuracy in financial disclosures [10]. - The company has received GMP certification for various products, including caffeine and aminophylline, with certifications HE20180061 and HE20180069, valid until August 16, 2023 [28]. - The company has established a comprehensive food safety quality control system, achieving multiple certifications including GMP and ISO standards [105]. Corporate Governance - The company maintains complete independence from its controlling shareholder in terms of business, assets, personnel, and finance, ensuring no interference in decision-making or operational activities [120]. - The board of directors operates in accordance with legal regulations and company bylaws, with specialized committees in place for strategic, remuneration, audit, and nomination functions [114]. - The supervisory board functions independently, ensuring effective oversight and compliance with legal and regulatory requirements [115]. - The company has established a performance evaluation and incentive mechanism for directors and senior management, with the remuneration and assessment committee overseeing the implementation of effective incentive and restraint measures [117]. Environmental Responsibility - The company has increased its investment in environmental protection and achieved clean production certification, demonstrating its commitment to social responsibility [44]. - The company has implemented a comprehensive energy management system to promote energy conservation and improve energy efficiency [157]. - The company reported no instances of exceeding pollution discharge standards for wastewater and waste gas [155]. - The company has committed to continuous improvement in environmental protection efforts, including regular monitoring by qualified third-party agencies [157]. Shareholder Relations and Dividends - The profit distribution plan approved by the board is to distribute a cash dividend of 1.5 RMB (including tax) for every 10 shares, with a capital reserve conversion of 8 shares for every 10 shares [2]. - The company distributed a cash dividend of RMB 1.50 per 10 shares, totaling RMB 97,561,846.20, which represents 100% of the total profit distribution [146]. - The company actively engages with investors through various communication channels to enhance transparency and trust [160]. Strategic Initiatives - The company is exploring new technologies in product formulation to improve efficacy and consumer satisfaction [33]. - The company has established measures to ensure stock price stability, which may include stock repurchases and other actions approved by the board and shareholders [169]. - The company has committed to measures to fill the diluted immediate return, focusing on improving operational efficiency and reducing costs [172].